Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
Active, not recruiting · NCT04068753 · Registry updated 2026-02-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 2 | 2026-02-10 | NCT04068753 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Tesaro, Inc. | 16 |
| University of Oklahoma | 146 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Louisiana State University Health Science Center | New Orleans | United States | 85 |
| Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis | United States | 1 |
| Stephenson Cancer Center | Oklahoma City | United States | 32 |
| University of Virginia Cancer Center | Charlottesville | United States | 11 |